Russell Investments Group Ltd. Sells 32,970 Shares of Integra LifeSciences Holdings Corporation $IART

Key Points

• Russell Investments Group Ltd. reduced its stake in Integra LifeSciences Holdings Corporation by 30.3%, selling 32,970 shares and maintaining 75,920 shares valued at $1,669,000.
• Integra's stock recently rose 3.4%, with a current trading price of $14.76 and a market cap of $1.15 billion, despite a challenging financial quarter with revenue down 0.6% year-over-year.
• Analysts have lowered their price targets for Integra LifeSciences, with Wells Fargo reducing its target from $25 to $13, indicating a more cautious outlook for the company's shares.

Russell Investments Group Ltd. cut its holdings in Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) by 30.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 75,920 shares of the life sciences company's stock after selling 32,970 shares during the period. Russell Investments Group Ltd. owned approximately 0.10% of Integra LifeSciences worth $1,669,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of IART. Assenagon Asset Management S.A. lifted its position in shares of Integra LifeSciences by 2,418.7% in the first quarter. Assenagon Asset Management S.A. now owns 1,799,944 shares of the life sciences company's stock worth $39,581,000 after buying an additional 1,728,480 shares during the last quarter. Soleus Capital Management L.P. bought a new stake in Integra LifeSciences during the fourth quarter worth approximately $28,940,000. Paradigm Capital Management Inc. NY grew its holdings in Integra LifeSciences by 170.3% during the fourth quarter. Paradigm Capital Management Inc. NY now owns 1,431,100 shares of the life sciences company's stock valued at $32,457,000 after purchasing an additional 901,600 shares during the last quarter. Systematic Financial Management LP raised its position in shares of Integra LifeSciences by 40.7% in the fourth quarter. Systematic Financial Management LP now owns 860,563 shares of the life sciences company's stock valued at $19,518,000 after purchasing an additional 248,817 shares during the period. Finally, Nuveen LLC acquired a new stake in shares of Integra LifeSciences in the first quarter worth $5,118,000. 84.78% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

IART has been the topic of several recent analyst reports. JMP Securities dropped their target price on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a report on Friday, May 9th. JPMorgan Chase & Co. cut their price objective on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Finally, Wells Fargo & Company decreased their target price on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Two analysts have rated the stock with a Buy rating, three have assigned a Hold rating and four have given a Sell rating to the company. According to MarketBeat, the company has an average rating of "Reduce" and an average target price of $18.43.

Integra LifeSciences Stock Performance

Shares of NASDAQ:IART traded up $0.29 during trading on Monday, hitting $15.13. 1,189,457 shares of the stock were exchanged, compared to its average volume of 1,423,225. The company has a market capitalization of $1.18 billion, a price-to-earnings ratio of -2.32, a price-to-earnings-growth ratio of 0.85 and a beta of 1.20. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.73 and a current ratio of 1.23. Integra LifeSciences Holdings Corporation has a 1-year low of $11.06 and a 1-year high of $27.13. The company's fifty day simple moving average is $13.12 and its 200-day simple moving average is $15.90.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its earnings results on Thursday, July 31st. The life sciences company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.43 by $0.02. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%.The firm had revenue of $415.61 million during the quarter, compared to analysts' expectations of $395.06 million. During the same period last year, the business earned $0.63 earnings per share. Integra LifeSciences's quarterly revenue was down .6% compared to the same quarter last year. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. Sell-side analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.